Exparel Approved for Postsurgical Pain Management

EXPAREL (bupivacaine liposome) 1.3% injectable suspension by Pacira
EXPAREL (bupivacaine liposome) 1.3% injectable suspension by Pacira
Pacira Pharmaceuticals announced that the FDA has approved Exparel (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia. This approval was based on data from 10 randomized, double-blind, clinical trials evaluating Exparel in 823 patients. In a pivotal hemorrhoidectomy trial of Exparel compared to placebo, where all patients with inadequate pain control received opioids for rescue pain relief, Exparel demonstrated significant reductions in cumulative pain scores with an attendant decrease in opioid consumption for up to 72 hours.

Exparel, a multivesicular, non-opioid, liposome, local anesthetic combines bupivacaine with DepoFoam, a product delivery technology that releases medication over a desired period of time.

For more information call (973) 254-3560 or visit www.exparel.com.